drugset
drugset / Trial / NCT05454020

A Study of Topical XG004 in Participants With Osteoarthritis of the Knee

NCT05454020 ↗

Phase 1 Completed 32 enrolled Xgene Pharmaceutical Group Novotech (Australia) Pty Limited · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This is phase 1 placebo controlled study to evaluate the safety, tolerability and pharmacokinetics of XG004 applied topically in participants with osteoarthritis of the knee

Timeline

Start
2022-06-07
Primary completion
2023-01-23
Completion
2023-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject XG004 Unknown 5 % Topical
Subject XG004 Unknown 10 % Topical

Indications

No indication recorded.